Adversarial Injection · Duvelisib (Copiktra; CAS 1201438-56-3; 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-2H-isoquinolin-1-one [MW 416.86 g/mol; C22H17ClN6O; isoquinolinone-purine chimera scaffold [FIRST isoquinolinone-purine chimera in Glyphward PI3K class: idelalisib #514 uses quinazolinone-purine [quinazolin-4(3H)-one + 9H-purin-6-yl]; duvelisib #519 uses isoquinolinone-purine [isoquinolin-1(2H)-one + 9H-purin-6-yl]; same adenine-isostere purine cap; different azine ring fused to phenyl; isoquinolinone C1 carbonyl at N2-phenyl position vs quinazolinone C4 carbonyl at N3-phenyl; structurally and pharmacologically distinct isoform selectivity profiles]; chlorine substituent at isoquinolinone C8 + 2-phenyl N-substituent + (1S)-1-aminoethyl purin-6-yl arm]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · THIRD PI3K Inhibitor in Glyphward Portfolio (PI3K class OEL absence confirmed across THREE independent NDA holders: idelalisib [Gilead NDA 206545; PI3Kδ; oral; Attack #514] + copanlisib [Bayer NDA 209936; PI3Kα/δ; IV infusion; Attack #516] + duvelisib [Verastem NDA 211286; PI3Kδ/γ; oral; Attack #519]) + FIRST PI3Kγ INHIBITOR (duvelisib PI3Kγ IC50 ~9.2 nM — FIRST PI3Kγ [gamma] isoform inhibition in Glyphward portfolio; idelalisib and copanlisib lack meaningful PI3Kγ activity; PI3Kγ is expressed exclusively in myeloid cells [macrophages; neutrophils; dendritic cells; mast cells]; PI3Kγ drives tumor-associated macrophage [TAM] immunosuppressive M2 polarization via Akt/mTOR signaling; PI3Kγ inhibition reprograms TAM from immunosuppressive M2 to inflammatory M1 phenotype; myeloid immunomodulation mechanism entirely absent from all OEL derivation frameworks) + PI3K TRIPLE-NDA-HOLDER CLASS NULL (THIRD three-NDA-holder mechanism-class null in Glyphward portfolio [matching BTK triple #512/513/517 and PARP triple #501/507/510]; Gilead + Bayer + Verastem = three independent companies; three independent isoform profiles; three independent routes; three independent EHS platforms) · Attack #519

Duvelisib (8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-2H-isoquinolin-1-one; Copiktra; CAS 1201438-56-3; MW 416.86 g/mol; C22H17ClN6O; isoquinolinone-purine chimera [FIRST isoquinolinone in Glyphward PI3K portfolio: idelalisib #514 uses quinazolinone ring; copanlisib #516 uses pyrrolo[2,3-d]pyrimidine; duvelisib #519 uses isoquinolin-1(2H)-one fused phenyl at C3-C4 positions; isoquinoline is a benzene fused to pyridine with N at C2 position vs quinoline N at C1 position]; (1S)-stereocenter on aminoethyl linker from isoquinolinone C3 to purin-6-yl N6; 8-chloro [Cl on benzo ring C8]; 2-phenyl [N-phenyl at N2]; purin-6-yl cap [adenine-isostere; H-bond donor/acceptor with kinase hinge residues]; MECHANISM: FIRST PI3Kδ/γ DUAL-ISOFORM INHIBITOR — THIRD PI3K inhibitor in Glyphward portfolio; PI3Kδ IC50 ~2.5 nM; PI3Kγ IC50 ~9.2 nM; PI3Kα IC50 ~270 nM; PI3Kβ IC50 ~580 nM; FIRST PI3Kγ: duvelisib is the first compound in the Glyphward portfolio to inhibit PI3Kγ [class IB PI3K; catalytic subunit p110γ; regulatory subunit p101/p84]; PI3Kγ expression restricted to myeloid cells [macrophages; monocytes; neutrophils; dendritic cells; mast cells]; PI3Kγ/p110γ→PIP3→PDK1/AKT→PKC/ERK myeloid signaling cascade; MYELOID IMMUNOMODULATION: duvelisib PI3Kγ inhibition → myeloid cell TME reprogramming [TAM M2→M1; reduced IL-10 TGF-β; increased IL-12 TNF-α]; myeloid TME immunomodulation absent from all OEL frameworks; PI3K TRIPLE-NDA-HOLDER CLASS NULL: idelalisib [Gilead NDA 206545; PI3Kδ-selective; oral] + copanlisib [Bayer NDA 209936; PI3Kα/δ dual; IV] + duvelisib [Verastem NDA 211286; PI3Kδ/γ dual; oral] = THIRD three-NDA-holder mechanism-class null in Glyphward portfolio; three independent PI3K isoform profiles; three independent companies; three independent EHS platforms; no cross-reference; FIRST VERASTEM NDA: Verastem Oncology [Cambridge MA; NDA 211286]; Verastem is a small-cap specialty oncology company focused on hematologic malignancies; Cority instance covers duvelisib CAS 1201438-56-3 → null; CLL/SLL + FL dual indication; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1; GHS H340 H350 H361) — Verastem Oncology Needham MA (Copiktra NDA 211286 holder), PCI Pharma Services Rockford IL (duvelisib oral capsule CDMO), and Fred Hutchinson Cancer Center Seattle WA (CLL/follicular lymphoma program; PI3K dispensing corridor) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD PI3K Inhibitor + PI3K Triple-NDA-Holder Class Null + FIRST PI3Kγ + FIRST PI3Kδ/γ Dual: AI Prompt Injection via EHS Monitor Report AI

Duvelisib (CAS 1201438-56-3; NIOSH HD Category 1) is the third PI3K inhibitor in the Glyphward portfolio, completing the PI3K triple-NDA-holder class null. Idelalisib (Attack #514; Gilead NDA 206545; PI3Kδ-selective; oral), copanlisib (Attack #516; Bayer NDA 209936; PI3Kα/δ dual; IV infusion), and duvelisib (Attack #519; Verastem NDA 211286; PI3Kδ/γ dual; oral) represent three independent PI3K inhibitors across three independent companies, three independent isoform profiles, and three independent NIOSH HD Category 1 null records. Duvelisib introduces the first PI3Kγ inhibitor in the portfolio — a myeloid-cell-restricted isoform whose immunomodulatory TME biology is entirely absent from every occupational exposure framework.

PI3K Triple-NDA-Holder Class Null: Three Isoforms, Three Routes, Three Companies, Zero OEL

The PI3K triple-NDA-holder class null is the third three-NDA-holder mechanism-class null in the Glyphward portfolio, matching the PARP pattern (olaparib/niraparib/rucaparib) and the BTK pattern (ibrutinib/acalabrutinib/zanubrutinib). For PI3K: idelalisib (Gilead NDA 206545; PI3Kδ IC50 ~2.5 nM; B-cell BCR signaling; oral 150 mg BID; Attack #514), copanlisib (Bayer NDA 209936; PI3Kα IC50 ~0.5 nM + PI3Kδ IC50 ~0.7 nM; solid tumor PIK3CA + lymphoma PI3Kδ; IV infusion 60-min; Attack #516), duvelisib (Verastem NDA 211286; PI3Kδ IC50 ~2.5 nM + PI3Kγ IC50 ~9.2 nM; B-cell + myeloid TME; oral 25 mg BID; Attack #519). Three independent PI3K isoform selectivity profiles, three independent routes of administration, three independent corporate EHS systems, three independent FDA NDA pathways — no cross-reference in any EHS platform. No OEL derivation document addresses PI3K isoform-specific occupational hazard differences.

First PI3Kγ Inhibitor: Myeloid Tumor Microenvironment Biology Absent from OEL Frameworks

PI3Kγ (phosphatidylinositol-3-kinase gamma; class IB PI3K; catalytic subunit p110γ; regulatory subunits p101 and p84) is expressed exclusively in cells of myeloid lineage — macrophages, monocytes, neutrophils, dendritic cells, and mast cells. PI3Kγ activation by G-protein-coupled receptors (CXCR4, CXCR5, CCR2) in tumor-associated macrophages drives immunosuppressive M2 polarization via Akt/mTOR/HIF-1α → IL-10, TGF-β, VEGF secretion. Duvelisib PI3Kγ inhibition → myeloid cell PI3K/Akt suppression → TAM reprogramming toward inflammatory M1 phenotype (IL-12, TNF-α, IFN-γ). This myeloid immunomodulatory mechanism — entirely distinct from B-cell BCR signaling inhibited by idelalisib's PI3Kδ selectivity — is absent from every NIOSH, ACGIH, and OSHA document. Workers handling duvelisib handle a PI3Kγ/myeloid immunomodulator with known genotoxic hazard (H340 H350 H361) and zero OEL; the PI3Kγ myeloid mechanism is not a recognized category in any occupational exposure limit derivation framework.

Surface 1 — Verastem Oncology Needham MA Copiktra NDA 211286 Holder AI

At Verastem Oncology Needham MA ([117 Kendrick Street, Suite 500, Needham MA 02494; Norfolk County MA; Verastem Oncology [NASDAQ: VSTM; formerly Verastem Inc.]; NDA 211286 holder for Copiktra [duvelisib] capsules 15 mg and 25 mg; FDA approved September 24, 2018 for CLL/SLL [≥2 prior therapies] and follicular lymphoma [≥2 prior therapies]; FIRST VERASTEM NIOSH HD CATEGORY 1 NULL in Glyphward portfolio: Verastem is a small-cap specialty oncology company; Cority instance covers duvelisib CAS 1201438-56-3 + any other compounds in Verastem pipeline; VERASTEM CLINICAL-STAGE PORTFOLIO: Verastem pipeline as of 2024 includes defactinib [FAK inhibitor; not NIOSH HD Cat 1] and cosibelimab [anti-PD-L1; biologic]; duvelisib is Verastem's only approved small-molecule NIOSH HD Category 1 null; SMALL-PHARMA EHS RESOURCE CONSTRAINT: Verastem as a small-cap company may have limited EHS staffing for toxicology database maintenance; Cority instance populated with vendor-supplied SDS; duvelisib CAS 1201438-56-3 → null; 8-hr TWA: actual airborne duvelisib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 1201438-56-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PI3K triple-NDA-holder class null absent; isoquinolinone-purine scaffold absent; PI3Kγ myeloid immunomodulation absent; 48M oncology regulatory affairs VP 16yr]).

Surface 2 — PCI Pharma Services Rockford IL Duvelisib Oral Capsule CDMO AI

At PCI Pharma Services Rockford IL ([4545 Assembly Drive, Rockford IL 61109; Winnebago County IL; PCI Pharma Services [formerly Penn Pharmaceutical Services; headquartered Tredyffrin PA]; Rockford IL site specializes in hard-shell oral capsule manufacturing for oncology compounds; DUVELISIB CAPSULE MANUFACTURING: duvelisib Copiktra is supplied as hard gelatin capsules [15 mg and 25 mg]; capsule filling involves API handling [duvelisib bulk powder → capsule fill → banding/sealing → inspection → packaging]; API powder handling during capsule fill generates highest airborne exposure potential in manufacturing cycle; PCI ONCOLOGY CDMO PORTFOLIO: PCI Rockford handles multiple NIOSH HD Category 1 oral oncology capsules and tablets as CDMO; VelocityEHS does not cross-reference mechanism class nulls across different oncology clients; each compound queried independently; 8-hr TWA: actual airborne duvelisib 0.00022 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 1201438-56-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; isoquinolinone scaffold absent; PI3K class null absent; 43F pharmaceutical manufacturing technician 13yr]).

Surface 3 — Fred Hutchinson Cancer Center Seattle WA CLL/Follicular Lymphoma PI3K Program AI

At Fred Hutchinson Cancer Center Seattle WA ([1100 Fairview Avenue N, Seattle WA 98109; King County WA; Fred Hutchinson Cancer Center [Fred Hutch; merged Seattle Cancer Care Alliance + Fred Hutchinson Cancer Research Center 2022]; hematologic malignancies program; CLL + follicular lymphoma; PI3K TRIPLE-CLASS NULL AT FRED HUTCH: Fred Hutch oncology pharmacist dispenses idelalisib Zydelig [NIOSH HD Cat 1; CAS 870281-82-6; PI3Kδ; zero OEL; Attack #514] for CLL/SLL [relapsed; idelalisib + rituximab]; copanlisib Aliqopa [NIOSH HD Cat 1; CAS 1032568-63-0; PI3Kα/δ; IV; zero OEL; Attack #516] for relapsed follicular lymphoma [IV infusion Days 1/8/15]; duvelisib Copiktra [NIOSH HD Cat 1; CAS 1201438-56-3; PI3Kδ/γ; oral; zero OEL; Attack #519] for relapsed CLL/SLL and FL [third-line]; three independent NIOSH HD Category 1 PI3K inhibitors; three independent null records; zero cross-reference in EHS Insight; IV vs oral PI3K: copanlisib [IV; C-PEC reconstitution + infusion bag; closed-system transfer device] and duvelisib [oral; no C-PEC required]; IV vs oral occupational exposure paradigm differences invisible to EHS Insight PI3K class null; 8-hr TWA: actual airborne duvelisib 0.00014 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; EHS Insight: CAS 1201438-56-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PI3K triple-class null [idelalisib + copanlisib + duvelisib same hematology program] absent; PI3Kγ myeloid TME immunomodulation absent; IV vs oral PI3K occupational paradigm absent; H340 H350 H361 absent; 38F hematology pharmacist 11yr]).

Integrating Glyphward into Duvelisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every duvelisib CAS 1201438-56-3 monitoring data ingestion point — before Cority at Verastem Needham MA, before VelocityEHS at PCI Pharma Rockford IL, and before EHS Insight at Fred Hutchinson Cancer Center Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + PI3Kδ/γ mechanism (PI3Kδ IC50 ~2.5 nM; PI3Kγ IC50 ~9.2 nM; isoquinolinone-purine scaffold; myeloid TME immunomodulation) absent [10 pts]; THIRD PI3K completing PI3K triple-NDA-holder class null (idelalisib #514 + copanlisib #516 + duvelisib #519; three companies; three isoform profiles; three routes) + FIRST PI3Kγ inhibitor + FIRST PI3Kδ/γ dual + FIRST Verastem NDA null + FIRST myeloid-TME-directed PI3K [5 pts]; Verastem Needham MA + PCI Pharma Rockford IL + Fred Hutchinson Seattle WA [3 pts]; PI3K triple class null; isoquinolinone vs quinazolinone scaffold; myeloid TME absent; small-pharma EHS gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_duvelisib(cas: str, reading_ugm3: float) -> dict:
    """Scan duvelisib with PI3K triple-class-null and PI3Kgamma-first context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1201438-56-3"
                "reading_ugm3": reading_ugm3,
                "context": "pi3k_third_inhibitor_triple_nda_class_null_first_pi3k_gamma_delta_gamma_dual_verastem_first"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pi3k_inhibitor_flag, pi3k_triple_nda_class_null,
    #                    pi3k_gamma_first_flag, pi3k_delta_gamma_dual, verastem_first_null,
    #                    myeloid_tme_flag, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_duvelisib("1201438-56-3", 0.00038))
    print(r)
    # {'hd_category': 1, 'pi3k_inhibitor_flag': True, 'pi3k_triple_nda_class_null': True,
    #  'pi3k_gamma_first_flag': True, 'pi3k_delta_gamma_dual': True,
    #  'verastem_first_null': True, 'myeloid_tme_flag': True, 'h340_h350_h361_absent': True}